We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Senescent CD4<sup>+</sup>CD28<sup>null</sup> cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of-concept pilot study.
- Authors
Amezcua-Guerra, Luis M.; Espinosa-Bautista, Fernanda; Hopf-Estandía, Karen; Valdivieso-Ruiz, Melisa; Coronel, Dania; Robledo, Sandra; Ramos-Rosillo, Varna; del Rocío Martínez-Alvarado, María; Patlán, Mariana; Páez, Araceli; Silveira, Luis H.; Tavera-Alonso, Claudia; Massó, Felipe; Soto-Fajardo, Carina; Pineda, Carlos
- Abstract
To characterize CD4+CD28null cells in chronic hyperuricemia and investigate whether allopurinol could restore CD28 expression and the balance of T helper phenotypes. Asymptomatic individuals with chronic hyperuricemia and ultrasonographic findings evocative of urate deposition in the joints. Age- and gender-matched normouricemic individuals were also studied. Oral allopurinol at 150 mg/day for 4 weeks, followed by 300 mg/day through week 12. Color-flow cytometry on peripheral blood mononuclear cells (PBMC) with antibodies against CD4, CD28, T-bet (Th1), GATA-3 (Th2), and RORγt (Th17). Six patients (five men, median age of 53 years) and seven controls were studied. At baseline, hyperuricemic patients had more CD4+CD28null/CD4+ cells than normouricemic subjects (36.8% vs. 6.1%; p = 0.001), with a predominance of T-bet+ cells (98.5% vs. 6.6%; p = 0.001) and few RORγt+ cells (0.7% vs. 89.4%; p = 0.014). In hyperuricemic patients, the number of CD4+ cells/10,000 PBMC was similar before and after allopurinol (3378 vs. 3954; p = 0.843). Conversely, CD4+CD28null cells decreased from 36.8% (23.0–43.7) to 15.8% (4.7–28.1; p = 0.031). CD4+CD28nullT-bet+ cells decreased from 98.5% (95.0–99.4) to 88.3% (75.2–98.9; p = 0.062), CD4+CD28nullGATA-3+ cells increased from 0% (0–4.0) to 2.8% (0.1–15.6; p = 0.156), and CD4+CD28nullRORγt+ cells increased from 0.7% (0.4–7.0) to 4.5% (1.3–28.1; p = 0.031). The CD4+CD28null cell subset is abnormally expanded in chronic hyperuricemia, despite the absence of overt urate-related disease. Allopurinol may partially restore CD28 expression on CD4+ cells while enhancing the homeostatic balance of T helper phenotypes. ClinicalTrials.gov, number NCT04012294. Key Points • Chronic hyperuricemia is characterized by an abnormal expansion of senescent CD4+CD28null cells, which are aberrantly polarized toward a Th1 effector phenotype. • Allopurinol administration restores CD28 expression on CD4+cells while enhancing the homeostatic balance of helper T phenotypes.
- Subjects
URATES; MONONUCLEAR leukocytes; HYPERURICEMIA; ALLOPURINOL; PROOF of concept; PHENOTYPES
- Publication
Clinical Rheumatology, 2023, Vol 42, Issue 8, p2181
- ISSN
0770-3198
- Publication type
Article
- DOI
10.1007/s10067-023-06595-8